drugset
drugset / Trial / NCT04281342

To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

NCT04281342 ↗

Phase 1 Completed 48 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverQuadruple-blindOther

Summary

To demonstrate that multiple-dose administration of oral therapeutic and supratherapeutic doses of aprocitentan do not have a clinically relevant effect on the QT interval.

Timeline

Start
2020-01-14
Primary completion
2021-08-03
Completion
2021-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprocitentan Small molecule 25 mg Oral
Subject Aprocitentan Small molecule 100 mg Oral

Indications

No indication recorded.